More on TGTX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $53.16 |
|
|||
| Open | $52.56 | ||||
| 52 Wk High | $14.87 | ||||
| 52 Wk Low | $4.90 | ||||
| Day High | $55.81 | ||||
| Day Low | $51.83 | ||||
| P/E | N/A | ||||
| EPS | $-0.67 | ||||
| Volume | 1,978,236 | ||||
- TG Therapeutics reports Phase 1 azer-cel data in progressive MS
- TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
- TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
- TG Therapeutics publishes five-year Briumvi comparison study
- TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
- TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
- Form 4 TG THERAPEUTICS, INC. For: Sep 10 Filed by: Charney Laurence N
- Form 144 TG THERAPEUTICS, INC. Filed by: Charney Laurence N
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Entities mentioned with TGTX
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- PDUFA | View Related Stories »
- AdCom | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
